MA44010A - Formulations pharmaceutiques de billes comprenant du diméthylfumarate - Google Patents

Formulations pharmaceutiques de billes comprenant du diméthylfumarate

Info

Publication number: MA44010A
Authority: MA; Morocco
Prior art keywords: dimethylfumarate; pharmaceutical formulations; formulations including; ball; ball pharmaceutical
Prior art date: 2016-02-11

Application number

MA044010A

Other languages

English (en)

Inventor

Shyam B Karki

Cheuk-Yui Leung

Yiqing Lin

Ivan Nestorov

Andrea Trementozzi

Kalyan Vasudevan

Jin Xu

Peter Zawaneh

Original Assignee

Biogen Ma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-11

Filing date

2017-02-08

Publication date

2018-12-19

2017-02-08 Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc

2018-12-19 Publication of MA44010A publication Critical patent/MA44010A/fr

Links

LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 title 1
229960004419 dimethyl fumarate Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA044010A 2016-02-11 2017-02-08 Formulations pharmaceutiques de billes comprenant du diméthylfumarate MA44010A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662294054P	2016-02-11	2016-02-11

Publications (1)

Publication Number	Publication Date
MA44010A true MA44010A (fr)	2018-12-19

Family

ID=58057304

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA044010A MA44010A (fr)	2016-02-11	2017-02-08	Formulations pharmaceutiques de billes comprenant du diméthylfumarate

Country Status (12)

Country	Link
US (2)	US11033509B2 (fr)
EP (1)	EP3413879A1 (fr)
JP (2)	JP6902043B2 (fr)
KR (1)	KR20180108814A (fr)
CN (1)	CN108778256A (fr)
AU (1)	AU2017217464B2 (fr)
CA (1)	CA3013472A1 (fr)
EA (1)	EA201891803A1 (fr)
IL (1)	IL261073A (fr)
MA (1)	MA44010A (fr)
MX (1)	MX391749B (fr)
WO (1)	WO2017139331A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3013472A1 (fr) *	2016-02-11	2017-08-17	Biogen Ma Inc.	Formulations pharmaceutiques de billes comprenant du dimethylfumarate
EP4090315A1 (fr) *	2020-01-17	2022-11-23	Société des Produits Nestlé S.A.	Forme posologique à comprimés de mélatonine à libération prolongée
AU2022285951A1 (en)	2021-06-04	2024-01-04	Zim Laboratories Limited	Delayed release compositions of dimethyl fumarate
CN115300616A (zh) *	2022-08-24	2022-11-08	韩永刚	一种单胃动物用的肠溶葡萄糖氧化酶固体分散体
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1799196T1 (sl) *	2004-10-08	2016-10-28	Forward Pharma A/S	Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
US20080187579A1 (en) *	2007-02-01	2008-08-07	Pavan Bhat	Extended-release dosage form
CA2862885C (fr) *	2012-02-07	2020-06-02	Biogen Ma Inc.	Compositions pharmaceutiques contenant du fumarate de dimethyle
US20150079180A1 (en) *	2013-09-18	2015-03-19	Xenoport, Inc.	Nanoparticle compositions of dimethyl fumarate
US10172794B2 (en) *	2013-12-13	2019-01-08	Biogen Ma Inc.	Controlled release dosage form for once daily administration of dimethyl fumarate
MA40982A (fr)	2014-11-19	2017-09-26	Biogen Ma Inc	Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
EA201890068A1 (ru)	2015-06-17	2018-09-28	Байоджен Ма Инк.	Частицы диметилфумарата и фармацевтические композиции на их основе
CN104971048B (zh) *	2015-07-01	2019-01-18	上海汇伦医药科技有限公司	富马酸二甲酯肠溶微丸及其制备方法
CA3013472A1 (fr) *	2016-02-11	2017-08-17	Biogen Ma Inc.	Formulations pharmaceutiques de billes comprenant du dimethylfumarate

2017
- 2017-02-08 CA CA3013472A patent/CA3013472A1/fr active Pending
- 2017-02-08 JP JP2018542269A patent/JP6902043B2/ja not_active Expired - Fee Related
- 2017-02-08 KR KR1020187025947A patent/KR20180108814A/ko not_active Ceased
- 2017-02-08 MA MA044010A patent/MA44010A/fr unknown
- 2017-02-08 WO PCT/US2017/016934 patent/WO2017139331A1/fr not_active Ceased
- 2017-02-08 CN CN201780016727.0A patent/CN108778256A/zh active Pending
- 2017-02-08 AU AU2017217464A patent/AU2017217464B2/en not_active Expired - Fee Related
- 2017-02-08 EP EP17706072.0A patent/EP3413879A1/fr not_active Withdrawn
- 2017-02-08 MX MX2018009749A patent/MX391749B/es unknown
- 2017-02-08 EA EA201891803A patent/EA201891803A1/ru unknown
- 2017-02-08 US US16/076,849 patent/US11033509B2/en not_active Expired - Fee Related
2018
- 2018-08-09 IL IL261073A patent/IL261073A/en unknown
2021
- 2021-05-13 US US17/319,694 patent/US20210369629A1/en not_active Abandoned
- 2021-06-18 JP JP2021101599A patent/JP2021152050A/ja active Pending

Also Published As

Publication number	Publication date
US20190046456A1 (en)	2019-02-14
KR20180108814A (ko)	2018-10-04
CA3013472A1 (fr)	2017-08-17
IL261073A (en)	2018-10-31
US20210369629A1 (en)	2021-12-02
JP2019504859A (ja)	2019-02-21
US11033509B2 (en)	2021-06-15
MX391749B (es)	2025-03-21
EP3413879A1 (fr)	2018-12-19
WO2017139331A8 (fr)	2017-10-12
MX2018009749A (es)	2019-02-07
EA201891803A1 (ru)	2019-01-31
CN108778256A (zh)	2018-11-09
AU2017217464B2 (en)	2022-11-10
JP2021152050A (ja)	2021-09-30
WO2017139331A1 (fr)	2017-08-17
JP6902043B2 (ja)	2021-07-14
AU2017217464A1 (en)	2018-08-30

Publication	Publication Date	Title
EP3817722A4 (fr)	2022-03-23	Compositions pharmaceutiques comprenant du méloxicam
MA50541A (fr)	2021-04-07	Formulations pharmaceutiques
EP3541385A4 (fr)	2020-06-24	Formulations pharmaceutiques
MA42303A (fr)	2018-05-09	Formulations pharmaceutiques
EP3349796A4 (fr)	2019-05-29	Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
MA54716A (fr)	2021-11-17	Réduction de la viscosité de formulations pharmaceutiques
DK3709978T3 (da)	2023-06-12	Farmaceutisk oral formulering omfattende bakterier
MA43705A (fr)	2018-11-28	Formulation pharmaceutique
DK3634377T3 (da)	2021-08-30	Farmaceutisk formulering
MA49977A (fr)	2020-01-15	Combinaisons pharmaceutiques comprenant un anticorps anti-ly75
MA45187A (fr)	2019-04-10	Combinaisons pharmaceutiques
EP3454847A4 (fr)	2019-12-18	Formulations de médicaments améliorées
EP3285768A4 (fr)	2019-01-09	Compositions pharmaceutiques comprenant du lonafarnib et du ritonavir
EP3694522A4 (fr)	2021-08-04	Formulation de comprimé pharmaceutique bicouche
MA40982A (fr)	2017-09-26	Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
EP3383371C0 (fr)	2024-05-01	Formulation pharmaceutique
MA49837A (fr)	2020-06-17	Compositions pharmaceutiques
DK3280447T3 (da)	2019-05-13	Farmaceutiske formuleringer
EP3389633A4 (fr)	2019-08-07	Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
MA49822A (fr)	2020-06-17	Combinaison pharmaceutique comprenant du ponesimod
EP3337463A4 (fr)	2019-04-03	Formulations pharmaceutiques
EP3706731A4 (fr)	2021-08-18	Formulations améliorées de médicaments
EP3638211A4 (fr)	2021-03-24	Compositions pharmaceutiques à libération prolongée retardée
DK3463365T3 (da)	2021-09-20	Farmaceutisk antifungal formulering
MA54095A (fr)	2022-02-09	Formulations pharmaceutiques aqueuses